Antipsychotic polypharmacy in schizophrenia in Canada

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1296, 2001-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks

By Barnes Thomas R.E.   Paton Carol  

CNS Drugs, Vol. 25, Iss. 5, 2011-05 ,pp. : 383-399

Adis International

Access to resources Recommend Favorite

Antipsychotic Polypharmacy

By  

Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. : 2231-2238

Bentham Science Publishers

Access to resources Recommend Favorite

Increase in Antipsychotic Polypharmacy Treatment in Patients with Schizophrenia Between 1994-2000 and 2010

By Ceylan Deniz   Aktener Ahmet   B. Akdede Berna   Alptekin Koksal  

Current Psychopharmacology, Vol. 3, Iss. 2, 2014-08 ,pp. : 108-112

Bentham Science Publishers

Access to resources Recommend Favorite

Increase in Antipsychotic Polypharmacy Treatment in Patients with Schizophrenia Between 1994-2000 and 2010

By  

Current Psychopharmacology, Vol. 3, Iss. 2, 2014-08 ,pp. : 108-112

Bentham Science Publishers

Access to resources Recommend Favorite

Safety and tolerability of antipsychotic polypharmacy

By Gallego Juan A   Nielsen Jimmi   De Hert Marc   Kane John M   Correll Christoph U  

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 527-542

Informa Healthcare

Access to resources Recommend Favorite